Blog

Scientific Communication: Writing & Presentation Tips

Rachel Gamburg — Tue, 31 Mar 2026 13:35:01 GMT

Why Is Scientific Communication Important?

As researchers, we spend weeks, months, and even years building a strong collective body of scientific knowledge. The value of our discoveries and insights can impact several pharma-related stakeholders, including hospitals and other institutions, healthcare professionals, manufacturers, and most importantly, patients. But how can we translate scientific breakthroughs into real impact? Effective communication tailored to each individual audience is essential to conveying the results and the impact of scientific insights. The value of our work can only be recognized by a broader audience if we communicate effectively. If we don’t, important discoveries are lost and underappreciated. Scientific communication comes in a variety of forms, such as written communication and presentations, including slide decks and verbal communication. Both written communication and presentations use unique strategies, although the core idea is the same: delivering content in digestible ways.

AI-Powered Commercial Intelligence for Pharma Sales & Field Force

puneet.bhatia@axtria.com (Puneet S. Bhatia) — Wed, 19 Mar 2025 15:15:37 GMT

The life sciences industry is experiencing a fundamental shift in how sales, marketing, and field operations function. The rapid evolution of customer expectations, digital transformation, and an explosion of data require commercial teams to move beyond traditional engagement models and embrace AI-powered execution. However, many organizations still struggle with siloed intelligence, preventing seamless collaboration across brand planning, sales execution, and HCP engagement.

Cell & Gene Therapies for Rare Diseases: The Power of RWD

javed.shaikh@axtria.com (Javed Shaikh) — Tue, 11 Feb 2025 11:23:49 GMT

Rare diseases are classified according to their prevalence within a population. In the United States, the Rare Diseases Act of 2002 specifies that a rare disease impacts fewer than 200,000 individuals. Collectively, there are over 7,000 rare diseases affecting more than 30 million people. A significant number of these conditions are life-threatening, and the majority lack available treatments.^{1, 2} In contrast, the European Commission defines rare diseases as chronic or life-threatening conditions that impact fewer than 1 in 2,000 individuals, equivalent to approximately 50 per 100,000 people. An estimated 27 - 36 million people in the EU live with a rare disease, with around 6,000 to 8,000 distinct rare diseases identified.³

Promotional Blackouts on Baseline Sales Dynamics in Marketing Strategy

hemant.kumar1@axtria.com (Hemant Kumar) — Thu, 04 Jan 2024 08:13:43 GMT

Promotional blackouts, defined as strategically timed periods during which marketing promotions are intentionally withheld, have emerged as a noteworthy component of contemporary marketing strategies. This blog delves into the role of promotional blackouts, examining their impact on consumer behavior, brand perception, and overall marketing effectiveness. The blog touches upon the diverse motivations behind adopting promotional blackouts, from creating a sense of urgency and exclusivity to mitigating consumer fatigue. However, at the core, this blog will explore the nuanced relationship between promotional blackouts and baseline sales. It will investigate the extent to which these intentional breaks impact the long-term and non-promotional performance of drugs.

Should Pharma Companies Prioritize New-to-Brand Prescriptions?

minal.kapoor@axtria.com (Minal Kapoor) — Wed, 13 Dec 2023 09:35:15 GMT

In the complex world of pharmaceuticals, where drug discovery, development, and marketing involve staggering investments and high-stakes decisions, one question looms large: should pharma companies care about new-to-brand patients? Answering this question could determine whether pharma companies succeed or fail during their market exclusivity phase.

Orchestrating Omnichannel Measurement for Personalized Campaigns

ritu.kohli@axtria.com (Ritu Kohli) — Tue, 03 Oct 2023 04:48:45 GMT

The Growth of Digital Investment

Pharma’s investment in digital marketing has grown significantly in the last few years, fueled by the proliferation of new channels, post-pandemic changes, and evolving customer preferences. Digital direct-to-consumer (DTC) media spending has surged 45% in the last year.¹ Paid advertising, websites, and social media are the biggest gainers, especially in the US market. And social channels such as Doximity, LinkedIn, and X (formerly Twitter) in the US, WeChat and DXY in China, and Line in Japan have gained popularity for HCP outreach.

Thanks to this rapid evolvement of the digital environment, customers now choose how and where they want to connect to you in a unique and on-demand manner. They interact with multiple channels at each stage of brand adoption, resulting in unique, non-linear journeys. That means we must ensure an outcomes-driven approach to measuring and optimizing omnichannel campaigns. Traditional approaches have several problems, including siloed measurement across online and offline channels, non-availability of granular datasets, lack of in-campaign analytics, and more.

Learn More - "Why Is Balancing Autonomy Critical To Driving Omnichannel Orchestration At Scale?"

Marketing Mix Analysis: Driving Next Best Actions Strategy

connect@axtria.com (Axtria Connect) — Mon, 26 Dec 2022 07:45:23 GMT

Traditional marketing looks at promotional activities in isolation. For example, a direct-to-consumer (DTC) manager focuses only on DTC content, such as which slots to buy across channels. A sales force (SF) manager focuses on which healthcare professionals (HCPs) to detail and with what frequency. However, looking at the channels in isolation is misleading as this approach ignores the interaction between channels and whether it is complementary or non-complementary. Failure to consider how channels interact may lead to misrepresenting the actual value generated by them. Marketing Mix (MMx) analysis and next best actions (NBAs) can solve this problem.

AI and ML in Pharma Industry | TinyML, AutoML, NLP

connect@axtria.com (Axtria Connect) — Tue, 20 Dec 2022 08:24:00 GMT

In these unprecedented times, the value of data science is clear, especially in the pharma and life sciences industries. The emergence of data science has brought access to technologies like deep learning, natural language processing (NLP), machine learning (ML), and imaging backed by artificial intelligence (AI) algorithms. This ever-changing technology is rapidly transforming how the pharma and life sciences industries operate.

Large pharma organizations are under constant pressure to reduce the time and cost of developing new drugs, and the rapid development and marketing of the COVID-19 vaccine changed the norms of operation for the entire industry. While the urgent drug-development measures taken during the COVID-19 crisis do not apply to the typical drug development and commercialization process, it has undoubtedly made pharma companies and the Food and Drug Administration (FDA) rethink many factors. Companies now realize that without making significant advancements and innovations in technology, they cannot compete with modern firms built on robust digital strategies. The ability to leverage data science technology is imperative, not only for the commercialization of drugs but also at the back end for drug development and pharmacovigilance. It all starts with data – the “oil that feeds into systems” – and data science, which is the “engine that runs” to provide actionable insights at the right time and with the speed and accuracy required for decision-making. In the aftermath of COVID-19, life sciences companies want to leverage next-gen AI technologies to fuel their growth. Four of these technologies are discussed below:

What is AIOps - The Future of Traditional IT Ops | Axtria

Megha Kapadia — Fri, 16 Dec 2022 09:38:06 GMT

Everywhere we look, data is increasing in volume and complexity. Businesses are looking for new ways to take advantage of this valuable resource and enhance the speed and accuracy of decision-making. Technological innovations drive businesses to evolve, so IT operations teams face several challenges. IT teams need to keep up with rapid changes in technology. They also struggle to meet business teams’ high expectations for the quick resolution of service and reliability issues. To enable digital transformation, organizations must change the way they think about traditional IT. They must consider it an integral part of an organization’s brand rather than treating it as a cost center.

We can already see the impact of artificial intelligence (AI) in business functions such as marketing, procurement, customer service, and manufacturing. Now, businesses are combining big data, AI, and machine learning (ML) to enhance and partially replace a broad range of IT functions. This makes it possible to revamp traditional IT operations into artificial intelligence operations (AIOps) that can handle performance monitoring, data health analysis, service management, and more.

What is AIOps?

AIOps means performing IT operations with the help of artificial intelligence (AI). AIOps platforms leverage big data, collecting information from multiple IT tools and devices to automatically spot and react to real-time issues while still providing traditional historical analytics.

The potential automation of IT operations, according to management consulting firm Gartner:

Impact of Integrated Delivery Networks (IDN) on the MedTech Sales

connect@axtria.com (Axtria Connect) — Fri, 11 Nov 2022 09:19:09 GMT

Health systems have undergone a seemingly interminable transformation through an ever-increasing progression of mergers and acquisitions (M&A) activities that have escalated over the past decade. With its emphasis on accountable care and clinical integration, the Affordable Care Act helped accelerate the formation of integrated delivery networks (IDN). An IDN is an organization or health system that owns and operates a network of healthcare facilities. They often contain many different types of inpatient and outpatient care facilities, including hospitals, physician groups, health clinics, ambulatory surgery centers, and imaging centers. Due to the shift from volume to value in healthcare delivery, hospitals had to adapt as Accountable Care Organizations (ACOs) began to form.¹ While the pace of M&As initially slowed during the early part of the pandemic, the rate of consolidation within the industry not only returned to its previous tempo but accelerated, due in part to the injection of billions of dollars from COVID-19 aid directly to the health systems. Despite the current global health crisis, the driving forces behind the consolidation of these systems remain the same: